Unveil PowdAir Plus DPI designed for developing markets at RDD Europe 2017
H&T Presspart, manufacturer of components for metered dose inhalers (MDIs), announced a collaborative partnership with Hovione Technology, supporting a strategic plan to expand its portfolio of novel drug delivery systems (NDDS) in respiratory care. As part of the partnership, H&T Presspart has acquired the global rights to manufacture and commercialise a capsule-based dry powder inhaler (DPI) originated by Hovione. H&T Presspart unveiled an enhanced version of the DPI, which was marketed as PowdAir Plus, at Respiratory Drug Delivery (RDD) Europe 2017.
“This is a strategically significant partnership for H&T Presspart and underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for respiratory patients,” said Peter Schmelzer, Chairman, H&T Presspart. “This partnership supports our strategy to respond to the rapidly growing demand for dry powder inhalers across a range of needs, with this collaboration focused on providing a solution for developing markets.”
“As demand in developing markets is increasing, pharma companies are looking for devices that deliver reliable performance and meet high patient expectations for ease of use, but at a reduced cost,” said Schmelzer.
Most DPIs have been designed for developed markets and incorporate multiple components and complex mechanics. In contrast, PowdAir Plus is a complete unit with has no metal or separate parts, and was designed to be robust to withstand the mechanical stresses of frequent use. Throughout the design process, functionality was of utmost importance and PowdAir Plus delivers an effective dose of medication with each capsule in line with expected market performance. It is compatible with all capsule types (i.e. gelatine and HPMC) in size 3, so can be used with any dry powder medicines. A particularly novel design feature is the way in which the device opens the capsule once the tray is closed, removing the need for patients to actively pierce the capsule and reducing the number of operational steps. By enhancing ease of use, the design also removes the risk of errors that may affect a treatment’s efficacy.
PowdAir Plus is thus designed for advanced simplicity, ease of use and affordability, making it ideal for developing markets. Neat and compact, PowdAir Plus is both attractive and highly portable, and the novel all-plastic, four-component design minimises manufacturing assembly and production costs, whilst maximising ease of use.
“We are delighted with the collaboration with H&T Presspart. With our expertise in DPI invention, design and development and Presspart’s mastery of large scale industrialisation and global distribution,” said Peter Villax, CEO, Hovione Technology, a company founded by the shareholders of Hovione, a 58-year-old manufacturer of Active Pharmaceutical Ingredients (APIs).